A post-treatment blood test could inform future cancer therapy decisions, study shows

American College of Radiology to form early lung cancer detection registry

The American College of Radiology Lung Cancer Screening Registry is expanding and will evolve into the Early Lung Cancer Detection Registry in late 2025.

March 14, 2025

Vol.51 No.10

Clinical Roundup

Combination therapy may overcome drug resistance in lung cancer with common KRAS mutation

Scientists at VCU Massey Comprehensive Cancer Center found that combination therapy of sotorasib (Lumakras)—an FDA-approved drug in the market—and an experimental drug called FGTI-2734, could make precision medicine more effective for patients with a highly resistant form of lung cancer.

March 14, 2025

Vol.51 No.10

Drugs & Targets

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

FDA granted Orphan Drug designation to rhenium obisbemeda (186Re) for the treatment of leptomeningeal metastases in patients with lung cancer.

March 14, 2025

Vol.51 No.10

In Brief

IU starts mobile lung cancer screening program

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center and IU Health began a mobile lung cancer screening program, which includes a 40-foot truck with a CT scanner.

March 07, 2025

Vol.51 No.09

Drugs & Targets

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

FDA granted priority review to Boehringer Ingelheim’s new drug application for BI 1810631 (zongertinib) for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have HER2 mutations and who have received prior systemic therapy.

February 21, 2025

Vol.51 No.07

Cancer History Project Podcast

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

Two decades ago, the discovery of the EGFR mutation transformed lung cancer treatment. The finding led to dramatically improved survival rates and ushered in the era of precision medicine and molecular profiling for lung cancer.

February 14, 2025

Vol.51 No.06

By Yiqing Wang

A post-treatment blood test could inform future cancer therapy decisions, study shows

YOU MAY BE INTERESTED IN

American College of Radiology to form early lung cancer detection registry

Combination therapy may overcome drug resistance in lung cancer with common KRAS mutation

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

IU starts mobile lung cancer screening program

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

Renew today!

Subscriber content

Never miss an issue!

Login